NCT05862896

Brief Summary

This study aims to identify if breathless patients with Long COVID have reduced transfer factor on pulmonary function testing and if the degree of transfer factor reduction is correlated with the symptom severity and physiological ability to exercise. We will also investigate whether a new type of X-ray called a dynamic chest X-ray can identify perfusion abnormalities and whether these correlate with differences in diffusion capacity measured on a pulmonary function test.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
194

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Aug 2023

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 16, 2023

Completed
1 day until next milestone

First Posted

Study publicly available on registry

May 17, 2023

Completed
3 months until next milestone

Study Start

First participant enrolled

August 1, 2023

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2024

Completed
Last Updated

May 17, 2023

Status Verified

May 1, 2023

Enrollment Period

1 year

First QC Date

May 16, 2023

Last Update Submit

May 16, 2023

Conditions

Keywords

Long COVID

Outcome Measures

Primary Outcomes (1)

  • Primary objective

    1\) To establish the proportion of patients with long COVID that have abnormal transfer factor on pulmonary function testing.

    12 months

Study Arms (2)

Control

Healthy, age and sex matched controls

Long Covid

Patients with breathlessness (defined as self-reported modified Borg Scale score of 2 or more when walking on flat ground for 100 metres) that has continued or developed and persists more than 4 weeks after acute COVID 19 i.e., related to 'long COVID' (covid confirmed by photographic evidence of positive lateral flow/NHS application, EMIS records or hospital lab data).

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

A group of adults (over 18 years) with breathlessness secondary to long COVID identified in the community will be compared with a control group of age and sex matched healthy volunteers.

You may qualify if:

  • Adults (over 18 years old)
  • Patients with breathlessness (defined as self-reported modified Borg Scale score of 2 or more when walking on flat ground for 100 metres) that has continued or developed and persists more than 4 weeks after acute COVID 19 i.e., related to 'long COVID' (covid confirmed by photographic evidence of positive lateral flow/NHS application, EMIS records or hospital lab data).
  • Able to achieve positioning for a PA chest X-ray for a 20 second period
  • Able to hold their breath for at least 7 seconds
  • Fluent spoken English - to ensure a comprehensive understanding of the research project and their proposed involvement
  • Able to provide written informed consent
  • For control group: Age, sex matched to participants identified in the affected group

You may not qualify if:

  • Any contraindication to pulmonary function testing or DCR
  • Pregnancy
  • For women of childbearing age, a positive pregnancy test or refusal of pregnancy test (a negative urinary pregnancy test on the day of DCR is a requirement)
  • Significant other respiratory co-morbidities as judged by study clinician
  • Significant research related radiation exposure in last 12 months prior to consent (from participation in a previous studies involving radiation exposure, with a research dose constraint of 0.4 mSv)
  • Unable to provide informed consent for any reason
  • For the long covid arm no evidence of a positive covid-19 test

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

COVID-19Post-Acute COVID-19 Syndrome

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesPost-Infectious DisordersChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 16, 2023

First Posted

May 17, 2023

Study Start

August 1, 2023

Primary Completion

August 1, 2024

Study Completion

August 1, 2024

Last Updated

May 17, 2023

Record last verified: 2023-05